Rxo (RXO) Other Non-Current Liabilities (2021 - 2026)

Rxo (RXO) has reported Other Non-Current Liabilities for 6 consecutive years, with $63.0 million the latest figure, recorded in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $63.0 million, down 28.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $63.0 million (down 28.41% YoY), and the FY2025 annual result was $69.0 million, down 16.87% from the prior year.
• Other Non-Current Liabilities was $63.0 million for Q1 2026 at Rxo, down from $69.0 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $88.0 million in Q1 2025 and troughed at $36.0 million in Q3 2022.
• Average Other Non-Current Liabilities over 5 years is $54.7 million, with a median of $42.0 million recorded in 2024.
• Year-over-year, Other Non-Current Liabilities jumped 114.63% in 2025 and decreased 28.41% in 2026.
• Over 5 years, Other Non-Current Liabilities stood at $40.0 million in 2022, then changed by 0.0% to $40.0 million in 2023, then surged by 107.5% to $83.0 million in 2024, then decreased by 16.87% to $69.0 million in 2025, then slipped by 8.7% to $63.0 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $63.0 million in Q1 2026, $69.0 million in Q4 2025, and $71.0 million in Q3 2025.